Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Reported Late Thursday, UroGen Announces New Data From The OLYMPUS Trial that Shows Median Durability Of Response Of 28.9 Months For JELMYTO, A Non-Surgical, Chemoablative Treatment For Adults With Low-Grade Upper Tract Urothelial Cancer

--Results from this ongoing, non-interventional, rollover study were presented at the 23rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company

URGN

Read More

Reported Late Tuesday, Eisai And Biogen Present Full Results Of Lecanemab Phase 3 Confirmatory Clarity AD Study For Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease Conference: Primary And Key Secondary Endpoints Were Changed From Ba…

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: , Cambridge, Massachusetts, CEO: , Christopher A.

BIIB